The hypoglossal nucleus was recently identified as a key brain region in which the presence of TDP-43 pathology could accurately discriminate TDP-43 proteinopathy cases with clinical amyotrophic lateral sclerosis (ALS). The objective of the present study was to assess the hypoglossal nucleus in behavioral variant frontotemporal dementia (bvFTD), and determine whether TDP-43 in this region is associated with clinical ALS. Twenty-nine cases with neuropathological FTLD-TDP and clinical bvFTD that had not been previously assessed for hypoglossal TDP-43 pathology were included in this study. Of these 29 cases, 41% (n=12) had a dual diagnosis of bvFTD-ALS at presentation, all 100% (n=12) of which demonstrated hypoglossal TDP-43 pathology. Of the 59% (n=17) cohort that presented with pure bvFTD, 35% (n=6) were identified with hypoglossal TDP-43 pathology. Review of the case files of all pure bvFTD cases revealed evidence of possible or probable ALS in 5 of the 6 hypoglossal-positive cases (83%) towards the end of disease, and this was absent from all cases without such pathology. In conclusion, the present study validates grading the presence of TDP-43 in the hypoglossal nucleus for the pathological identification of bvFTD cases with clinical ALS, and extends this to include the identification of cases with possible ALS at end-stage.
INTRODUCTION
The TAR DNA-binding protein 43 (TDP-43) in behavioral variant frontotemporal dementia (bvFTD) was recently proposed to have a regional distribution, initiated in the orbitofrontal cortex and amygdala before progressing to the frontal and temporal cortices, eventually involving the motor system, visual cortex and cerebellum [5] . Although the majority of bvFTD cases were found to have TDP-43 pathology in motor system regions, less than half of these demonstrated clinical features suggestive or diagnostic of amyotrophic lateral sclerosis (ALS) [5] .
In our recent analysis, the hypoglossal nucleus emerged as a key brain region in which the presence of TDP-43 pathology could accurately discriminate 'TDP-43opathy' cases with coexistent clinical features of ALS [20] . However, TDP-43 pathology was seen in the hypoglossal nucleus of 13% of the bvFTD cohort assessed [20] . Based on the premise that pathological deposition precedes clinical symptomology [4] , the present study set out to determine if bvFTD cases with TDP-43 pathology in the hypoglossal nucleus had developed or were developing ALS by endstage.
MATERIAL AND METHODS

Case selection.
Cases with bvFTD were selected from a neuropathological series of cases collected by the Sydney Brain Bank through regional brain donor programs. The brain donor programs hold approval from the Human Research Ethics Committees of The University of New South Wales, and comply with the statement on human experimentation issued by the National Health and Medical Research Council of Australia. All cases had previously undergone standardized detailed neuropathological characterization [8, 14] . Patients with bvFTD were diagnosed during life by experienced clinicians using standard clinical diagnostic criteria [13, 16] following a medical interview, cognitive testing and an informant history. Standardized tests were used to longitudinally follow patients and controls, with their last assessments performed within 14 months of death. Clinical data were ascertained from an integrated clinical and neuropathological database and by retrospective review of patient clinical files. This research project was approved by the Human Research Ethics Committee of the University of New South Wales. Cases with neuropathological FTLD-TDP and clinical bvFTD not previously analysed in [20] were included in this study (n=27) as well as two bvFTD cases previously assessed that met clinical criteria for possible ALS by endstage (n=2/22 from [20] Figure 2c ). Of these 29 bvFTD cases, 59% (n=17) did not have a clinical diagnosis of possible or probable ALS at onset and are referred to here as 'pure bvFTD' while the others had both bvFTD and possible or probable ALS at onset (n=12, 41%). immunostaining was also performed on sections from the motor cortex and where available, the spinal cord. The severity of TDP-43 pathology in each section was graded on a four-point severity scale: 0 = no detectable pathology, 1 = mild pathology, 2 = moderate and 3 = frequent pathology.
Analysis of TDP
Assessments of TDP-43 pathology were performed by two raters blind to case details with an interand intra-rater variance of <5%. 
Frozen tissue.
Frozen tissue was available in 75% (n=9) of bvFTD-ALS and 76% (n=12) of pure bvFTD cases, and was screened for genetic mutations (C9ORF72 and GRN) using previously published methods [12, 17] . Table 1 here XX 2.4.2. P62 and dipeptide repeat proteins in cerebellum. Formalin-fixed, paraffin-embedded tissue blocks of the cerebellum cortex were available for 67% (n=8) of bvFTD-ALS and 76% (n=13) pure bvFTD cases, and were sectioned at 10 μm, and immunostained with antibodies to p62 (cat #610833, BD Biosciences, 1:500), phosphorylated TDP-43 (TIP-PTD-M01, Cosmo Bio, 1:80 000) and poly-GA (specificity detailed previously [15] , courtesy of Prof M Hasegawa, 1:1500). All slides were counterstained with haematoxylin to visualize neurons, and assessments for P62 and dipeptide repeat protein inclusions characteristic of C9ORF72 expansions [2, 15] were performed at 200-400x magnification.
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Statistical analyses.
Statistical analyses were performed using SPSS (IBM SPSS statistics version 21; SPSS Inc.), with p-values < 0.05 taken as significant. Demographic data were plotted and checked for normality of distribution by Kolmogorov-Smirnov tests. Parametric data (age at onset and death, disease duration, postmortem interval, brainstem weight, brain weight) were assessed across participant groups via one-way ANOVA followed by Bonferroni post hoc tests.
Variables showing non-parametric distribution were analysed using chi-square analyses (gender, mutation).
RESULTS
TDP-43 pathology in bvFTD cases
. TDP-43 cytoplasmic inclusions were identified in the hypoglossal nucleus of 100% (n=12) of the bvFTD-ALS cases and 29% (n=5) of the pure bvFTD cases. Punctate TDP-43 granules similar to that previously described [11] were identified in the hypoglossal nucleus and spinal cord in a further 6% (n=1) of the pure bvFTD cases ( Figure 1 ). All bvFTD cases with TDP-43 pathology in the hypoglossal nucleus (n=6) were found to have TDP-43 pathology in the motor cortex (Table 2 ) and a further 55% (n=6) of bvFTD cases without TDP-43 pathology in the hypoglossal nucleus demonstrated TDP-43 pathology in the motor cortex. Table 2 here XX 3.2 End-stage ALS in bvFTD cohort. The clinical records of all pure bvFTD cases (n=17) were retrospectively reviewed by a clinical neurologist (MK). Based on the Awaji-shima consensus recommendations for ALS [10] , motor impairment consistent with 'possible' and 'probable' ALS was identified in 24% (n=4) and 6% (n=1) cases respectively, in the final clinical reports performed outside of specialist ALS clinics.
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Evidence of genetic abnormalities in the bvFTD cohort.
3.3.1. Gene screening. Frozen tissue was available in 9/12 bvFTD-ALS cases. A C9ORF72 expansion was identified in 33% (n=3/9) of the bvFTD-ALS cases and 62% (n=8) of the pure bvFTD cases (Table 1) . A GRN mutation was identified in 24% (n=4) of the pure bvFTD cases only.
P62 and dipeptide repeat proteins in cerebellum.
All bvFTD-ALS (n=5) and pure bvFTD cases (n=9) assessed for both C9ORF72 expansions in frozen tissue and C9ORF72-distinct histopathology in cerebellar sections demonstrated consistent results with both methods. Of the bvFTD-ALS cases without available frozen tissue (3/12), C9ORF72-specific cerebellar pathology was identified in 33% bvFTD-ALS (1/3). C9ORF72-specific cerebellar pathology was not seen in 67% bvFTD-ALS (n=2) and 100% pure bvFTD cases (n=4).
Family history
Familial bvFTD.
Familial disease was present in 33% (n=4) of bvFTD-ALS and 76% (n=13) of pure bvFTD cases. For bvFTD-ALS, a C9ORF72 expansion was identified in 75% (n=3/4).
Within the familial bvFTD cohort, 62% (n=8/13) demonstrated a C9ORF72 expansion, 31%
(n=4/13) demonstrated a GRN mutation, and no mutation was identified in 8% (n=1/13).
Family history of ALS.
A family history for ALS was identified in 8% (n=1/12) of bvFTD-ALS cases and 24% (n=4/17) of pure bvFTD cases. All cases with a positive family history for ALS harbored a C9ORF72 expansion (n=5), and 80% (n=4) demonstrated maternal inheritance.
Clinicopathological findings.
Of the pure bvFTD cases identified to have TDP-43 pathology in the hypoglossal nucleus (n=6), 83% (n=5) corresponded with a retrospective diagnosis of end-stage possible or probable ALS. The remaining case (n=1) demonstrated no end-stage signs of motor dysfunction although the patient's very slim stature in the final years of disease was of note, particularly since she had been significantly overweight for the majority of the disease course.
There was no indication of clinical ALS in 100% (n=11) of the pure bvFTD cases without TDP-43 pathology in the hypoglossal nucleus.
Demographic features.
As can be seen in Table 1 , age at disease onset and death, gender and postmortem interval did not differ significantly across bvFTD groups (all p-values > 0.1).
Disease duration was significantly shorter in bvFTD-ALS cases compared to pure bvFTD cases as a whole (p < 0.005), but this difference was driven by pure bvFTD cases without TDP-43 pathology in the hypoglossal nucleus (p < 0.005). The frequency of C9ORF72 expansions was not significant between bvFTD-ALS and pure bvFTD cases as a whole. However, the separation of pure bvFTD cases by TDP-43 pathology in the hypoglossal nucleus revealed a higher frequency of C9ORF72 expansions in pure bvFTD cases with TDP-43 pathology in the hypoglossal nucleus compared to without (p < 0.05), and this significance held even in comparison to bvFTD-ALS cases (p < 0.05).
GRN expansions were only identified in pure bvFTD cases without TDP-43 pathology in the hypoglossal nucleus (p < 0.05 compared to other groups). Family history for ALS was more prevalent in pure bvFTD cases with TDP-43 in the hypoglossal nucleus, but this did not reach significance compared to other bvFTD cohorts (p = 0.06). The recent topographical staging of TDP-43 pathology in bvFTD and ALS [6, 7] demonstrated that TDP-43 initiated in the motor system network in ALS is also seen in the majority of bvFTD cases, despite the absence of ALS in over 50% of these [6, 21] . In a recent analysis [21] , we identified the hypoglossal nucleus as a key brain region in discriminating between cases with and without ALS and the present study corroborates this finding in bvFTD cases. Further support for the segregation of bvFTD cases by TDP-43 inclusions in the hypoglossal nucleus was evidenced here by differences in disease duration and postmortem brain weights, with 'intermediate' levels of atrophy in bvFTD cases with end-stage ALS (Figure 2 ). Motor system degeneration is characteristic of ALS [8] but neuroimaging studies have reported mild and often times variable atrophy in these regions rather than substantial atrophy [3, 9] . In contrast, the brainstem is one of the earliest regions affected in bvFTD due to its considerable non-motor cortical connectivity with cortical regions affected early in the disease [19] , Although sampled at the end of disease, the greater brain and brainstem weights seen in bvFTD cases with TDP-43 pathology in the hypoglossal nucleus suggest that structural analyses of brainstem integrity earlier in the disease course may be able to delineate these cases. Unfortunately, neuroimaging scans were not available in this present cohort and the feasibility of this could not be assessed here.
No GRN mutations were identified in bvFTD cases with TDP-43 pathology in the hypoglossal nucleus, and this converges with the very low prevalence of GRN mutations in ALS [18] to suggest that GRN mutations may identify bvFTD patients that have a lower risk of TDP-43 pathology in the hypoglossal nucleus and clinical ALS. Importantly, 50% of bvFTD cases with TDP-43 pathology in the hypoglossal nucleus harbored a C9ORF72 expansion and this was particularly prevalent in cases that had not been diagnosed with ALS at presentation (83%), emphasizing the need to follow C9ORF72-bvFTD cases longitudinally for early clinical signs of ALS.
In terms of limitations it is accepted that there remains a period of time between the final clinical assessment and patient death, during which further clinical features may have developed.
Although such a time lapse is difficult to circumvent, the replication of our current results in larger cohorts of patients represents an important avenue for future research to ascertain whether TDP-43 pathology in the hypoglossal nucleus precedes clinical ALS symptomology.
In summary, the present study validates the application of our recently proposed probabilistic [20] . 
